{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:27:41Z","timestamp":1780601261731,"version":"3.54.1"},"reference-count":90,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0296"],"award-info":[{"award-number":["W81XWH-21-1-0296"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA271540"],"award-info":[{"award-number":["1R01CA271540"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA273956"],"award-info":[{"award-number":["U54CA273956"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA231776"],"award-info":[{"award-number":["U01CA231776"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA212007"],"award-info":[{"award-number":["U01CA212007"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008719","name":"Movember Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008719","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.cpet.2025.01.001","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T07:30:57Z","timestamp":1738999857000},"page":"205-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrating Prostate Specific Membrane Antigen-PET into Clinical Practice for Prostate Cancer"],"prefix":"10.1016","volume":"20","author":[{"given":"Jarey H.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuoc T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Sutera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpet.2025.01.001_bib1","article-title":"GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries - bray - 2024 - CA","year":"2022","journal-title":"A\u00a0Cancer Journal for Clinicians"},{"issue":"8","key":"10.1016\/j.cpet.2025.01.001_bib2","doi-asserted-by":"crossref","first-page":"e2119568","DOI":"10.1001\/jamanetworkopen.2021.19568","article-title":"Causes of death among patients with metastatic prostate cancer in the US from 2000 to 2016","volume":"4","author":"Elmehrath","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10231","key":"10.1016\/j.cpet.2025.01.001_bib3","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.cpet.2025.01.001_bib4","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2025.01.001_bib5","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.001_bib6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.001_bib7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN Guidelines\u00ae insights: prostate cancer, version 3.2024: featured updates to the NCCN guidelines","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.cpet.2025.01.001_bib8","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, Part I: introduction, risk assessment, staging, and risk-based management","author":"Eastham","year":"2022","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.001_bib9","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"Psma pet\/ct: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2025.01.001_bib10","article-title":"Prospective validation of gallium-68 prostate specific membrane antigen-positron emission tomography\/computerized tomography for primary staging of prostate cancer","author":"van Kalmthout","year":"2020","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.001_bib11","first-page":"52","article-title":"A\u00a0phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.001_bib12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00259-020-04974-w","article-title":"Pelvic lymph-node staging with 18F-DCFPyL PET\/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -","volume":"48","author":"Jansen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.001_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"Chow","year":"2023","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.001_bib14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.euo.2021.02.006","article-title":"Combined utility of 68Ga-Prostate-specific membrane antigen positron emission tomography\/computed tomography and multiparametric magnetic resonance imaging in predicting prostate biopsy pathology","volume":"5","author":"Kalapara","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.cpet.2025.01.001_bib15","article-title":"68Ga-Prostate-Specific membrane antigen positron emission tomography maximum standardized uptake value as a predictor of gleason pattern 4 and pathological upgrading in intermediate-risk prostate cancer","author":"Xue","year":"2022","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.001_bib16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00259-020-04944-2","article-title":"68Ga-PSMA PET\/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer","volume":"48","author":"Roberts","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.001_bib17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/MNM.0000000000000942","article-title":"Can SUVmax values of Ga-68-PSMA PET\/CT scan predict the clinically significant prostate cancer?","volume":"40","author":"Demirci","year":"2019","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.cpet.2025.01.001_bib18","author":"Raveenthiran","year":"2022","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.001_bib19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.euo.2023.05.004","article-title":"Gallium-68 prostate-specific membrane antigen positron emission tomography\/computed tomography in active surveillance for prostate cancer trial (PASPoRT)","volume":"7","author":"Heetman","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.cpet.2025.01.001_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12894-023-01219-4","article-title":"Expanding the role of PSMA PET in active surveillance","volume":"23","author":"Jain","year":"2023","journal-title":"BMC Urol"},{"issue":"4","key":"10.1016\/j.cpet.2025.01.001_bib21","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.euo.2022.04.006","article-title":"Diagnostic performance of prostate-specific membrane antigen positron emission tomography\u2013targeted biopsy for detection of clinically significant prostate cancer: a systematic review and meta-analysis","volume":"5","author":"Kawada","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2025.01.001_bib22","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (primary): a prospective multicentre study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"issue":"S1","key":"10.1016\/j.cpet.2025.01.001_bib23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/bju.14794","volume":"124","author":"Scheltema","year":"2019","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.001_bib24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"issue":"S4","key":"10.1016\/j.cpet.2025.01.001_bib25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/bju.16214","article-title":"The CONFIRM trial protocol: the utility of prostate-specific membrane antigen positron emission tomography\/computed tomography in active surveillance for prostate cancer","volume":"133","author":"Bagguley","year":"2024","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.cpet.2025.01.001_bib26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.eururo.2023.06.018","article-title":"Diagnostic performance and safety of positron emission tomography with 18F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate- to very-high-risk prostate cancer: results from a phase 3, prospective, multicentre study (LIGHTHOUSE)","volume":"84","author":"Surasi","year":"2023","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.cpet.2025.01.001_bib27","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.cpet.2025.01.001_bib28","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.cpet.2025.01.001_bib29","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2967\/jnumed.118.209387","article-title":"Potential impact of 68Ga-PSMA-11 PET\/CT on the planning of definitive radiation therapy for prostate cancer","volume":"59","author":"Calais","year":"2018","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2025.01.001_bib30","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"issue":"4_suppl","key":"10.1016\/j.cpet.2025.01.001_bib31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.2024.42.4_suppl.291","article-title":"Update from the PSMA-dRT trial: a randomized phase III trial of PSMA-PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer","volume":"42","author":"Nikitas","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.001_bib32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12885-022-09283-z","article-title":"PSMA PET\/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial","volume":"22","author":"M\u00e9nard","year":"2022","journal-title":"BMC Cancer"},{"issue":"10288","key":"10.1016\/j.cpet.2025.01.001_bib33","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","article-title":"18F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial","volume":"397","author":"Jani","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.001_bib34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2021.05.006","article-title":"External validation and addition of prostate-specific membrane antigen positron emission tomography to the most frequently used nomograms for the prediction of pelvic lymph-node metastases: an international multicenter study","volume":"80","author":"Meijer","year":"2021","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.cpet.2025.01.001_bib35","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.eururo.2023.06.022","article-title":"Presurgical 68Ga-PSMA-11 positron emission tomography for biochemical recurrence risk assessment: a follow-up analysis of a multicenter prospective phase 3 imaging trial","volume":"84","author":"Dja\u00efleb","year":"2023","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.cpet.2025.01.001_bib36","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.cpet.2025.01.001_bib37","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1200\/JCO.21.02800","article-title":"Adjuvant versus early salvage radiation therapy after radical prostatectomy for pN1 prostate cancer and the risk of death","volume":"40","author":"Tilki","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.cpet.2025.01.001_bib38","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.2967\/jnumed.122.265368","article-title":"The association between [68Ga]PSMA PET\/CT response and biochemical progression in patients with high-risk prostate cancer receiving neoadjuvant therapy","volume":"64","author":"Chen","year":"2023","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2025.01.001_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/pros.24775","article-title":"Impact of definitive radiotherapy on metabolic response measured with 68Ga-PSMA-PET\/CT in patients with intermediate-risk prostate cancer","author":"Onal","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.cpet.2025.01.001_bib40","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline Part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy","author":"Morgan","year":"2024","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.cpet.2025.01.001_bib41","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline Part III: salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions","author":"Morgan","year":"2024","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.001_bib42","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II\u20142024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.cpet.2025.01.001_bib43","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2967\/jnumed.121.262412","article-title":"A\u00a0comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: results from a prospective multicenter study on 2,005 patients","volume":"63","author":"Abghari-Gerst","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"13","key":"10.1016\/j.cpet.2025.01.001_bib44","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2025.01.001_bib45","article-title":"Diagnostic performance and safety of 18F-rhPSMA-7.3 positron emission tomography in men with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT)","author":"Jani","year":"2023","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.001_bib46","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eururo.2024.01.012","article-title":"Impact of prostate-specific membrane antigen positron emission tomography\/computed tomography on prostate cancer salvage radiotherapy management: results from a prospective multicenter randomized phase 3 trial (PSMA-SRT NCT03582774)","volume":"86","author":"Armstrong","year":"2024","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.cpet.2025.01.001_bib47","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10336","key":"10.1016\/j.cpet.2025.01.001_bib48","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.cpet.2025.01.001_bib49","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2025.01.001_bib50","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","article-title":"Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies","volume":"73","author":"Gravis","year":"2018","journal-title":"Eur Urol"},{"issue":"10162","key":"10.1016\/j.cpet.2025.01.001_bib51","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.001_bib52","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"issue":"29","key":"10.1016\/j.cpet.2025.01.001_bib53","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.cpet.2025.01.001_bib54","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2020.38.6_suppl.10","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-year results\u00a0of a randomized phase II trial","volume":"38","author":"Ost","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.001_bib55","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.cpet.2025.01.001_bib56","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.001_bib57","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.clgc.2020.08.002","article-title":"Metastasis-directed therapy (SBRT) guided by PET-CT 18F-choline versus PET-CT 68Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness","volume":"19","author":"Mazzola","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.cpet.2025.01.001_bib58","first-page":"1","article-title":"PSMA-11-PET\/CT versus choline-PET\/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer","volume":"30","author":"Deijen","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2025.01.001_bib59","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2023.04.025","article-title":"Clinical and genomic differences between advanced molecular imaging-detected and conventional imaging-detected metachronous oligometastatic castration-sensitive prostate cancer","volume":"84","author":"Sutera","year":"2023","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.001_bib60","doi-asserted-by":"crossref","first-page":"100864","DOI":"10.1016\/j.adro.2021.100864","article-title":"Positron emission tomography-derived metrics predict the probability of local relapse after oligometastasis-directed ablative radiation therapy","volume":"7","author":"Greco","year":"2021","journal-title":"Adv Radiat Oncol"},{"issue":"7","key":"10.1016\/j.cpet.2025.01.001_bib61","doi-asserted-by":"crossref","first-page":"101507","DOI":"10.1016\/j.adro.2024.101507","article-title":"Prostate-specific membrane antigen PET response associates with metastasis-free survival after stereotactic ablative radiation in oligometastatic prostate cancer","volume":"9","author":"Sutera","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.cpet.2025.01.001_bib62","doi-asserted-by":"crossref","first-page":"110443","DOI":"10.1016\/j.radonc.2024.110443","article-title":"Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomics","volume":"199","author":"Cao","year":"2024","journal-title":"Radiother Oncol"},{"issue":"12","key":"10.1016\/j.cpet.2025.01.001_bib63","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10276","key":"10.1016\/j.cpet.2025.01.001_bib64","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.cpet.2025.01.001_bib65","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.cpet.2025.01.001_bib66","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.001_bib67","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.001_bib68","doi-asserted-by":"crossref","first-page":"e233460","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology"},{"issue":"10","key":"10.1016\/j.cpet.2025.01.001_bib69","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.2967\/jnumed.121.263441","article-title":"Outcome of patients with PSMA PET\/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis","volume":"63","author":"Hotta","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.001_bib70","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/pros.24104","article-title":"Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted \u03b2-emitting radionuclide therapies in metastatic castration-resistant prostate cancer","volume":"81","author":"Vlachostergios","year":"2021","journal-title":"Prostate"},{"issue":"8","key":"10.1016\/j.cpet.2025.01.001_bib71","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/pros.24518","article-title":"Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with 177Lu-PSMA-617. A single-center prospective observational study","volume":"83","author":"Telli","year":"2023","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.cpet.2025.01.001_bib72","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1007\/s00259-020-05160-8","article-title":"Prognostic implications of dual tracer PET\/CT: PSMA ligand and [(18)F]FDG PET\/CT in patients undergoing [(177)Lu]PSMA radioligand therapy","volume":"48","author":"Michalski","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.cpet.2025.01.001_bib73","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.001_bib74","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/MNM.0000000000001371","article-title":"Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system (\u2018Pro-PET\u2019 score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis","volume":"42","author":"Adnan","year":"2021","journal-title":"Nucl Med Commun"},{"issue":"supplement 2","key":"10.1016\/j.cpet.2025.01.001_bib75","first-page":"241044","article-title":"Eligibility to PSMA-RLT based on dual FDG\/PSMA-PET: a subanalysis of the 3TMPO study","volume":"65","author":"Beauregard","year":"2024","journal-title":"J\u00a0Nucl Med"},{"issue":"61","key":"10.1016\/j.cpet.2025.01.001_bib76","doi-asserted-by":"crossref","first-page":"103108","DOI":"10.18632\/oncotarget.21600","article-title":"Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy","volume":"8","author":"Ahmadzadehfar","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.001_bib77","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3390\/pharmaceutics13050722","article-title":"Efficacy and safety of [(225)Ac]Ac-PSMA-617 augmented [(177)Lu]Lu-PSMA-617 radioligand therapy in patients with highly advanced mCRPC with poor prognosis","volume":"13","author":"Rosar","year":"2021","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.cpet.2025.01.001_bib78","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and Objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.cpet.2025.01.001_bib79","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","article-title":"Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria","volume":"49","author":"Gafita","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.001_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00302","article-title":"Multimodal approach to outcome prediction in metastatic castration-resistant prostate cancer by integrating functional imaging and plasma DNA analysis","author":"Conteduca","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.001_bib81","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","article-title":"Prostate-specific membrane antigen reporting and data system version 2.0","volume":"84","author":"Werner","year":"2023","journal-title":"Eur Urol"},{"issue":"Suppl 1","key":"10.1016\/j.cpet.2025.01.001_bib82","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving Considerations for PET response criteria in solid tumors","volume":"50 Suppl 1","author":"Wahl","year":"2009","journal-title":"J\u00a0Nucl Med"},{"issue":"11","key":"10.1016\/j.cpet.2025.01.001_bib83","first-page":"1651","article-title":"Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study","volume":"63","author":"Gafita","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.001_bib84","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2967\/jnumed.119.233817","article-title":"Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET\/CT imaging: the PSMA PET progression criteria","volume":"61","author":"Fanti","year":"2020","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.001_bib85","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cpet.2024.03.002","article-title":"Prostate-specific membrane antigen","volume":"19","author":"Seifert","year":"2024","journal-title":"Pet Clin"},{"issue":"12","key":"10.1016\/j.cpet.2025.01.001_bib86","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2967\/jnumed.123.265874","article-title":"PSMA PET\/CT for response assessment and overall survival prediction in patients with metastatic castration-resistant prostate cancer treated with androgen receptor pathway inhibitors","volume":"64","author":"Shagera","year":"2023","journal-title":"J\u00a0Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2025.01.001_bib87","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis","volume":"63","author":"H\u00f6vels","year":"2008","journal-title":"Clin Radiol"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.001_bib88","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/RLU.0b013e3182867f3c","article-title":"Choline PET or PET\/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis","volume":"38","author":"Evangelista","year":"2013","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.001_bib89","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00259-015-3202-7","article-title":"PET\/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data","volume":"43","author":"Fanti","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2025.01.001_bib90","article-title":"The diagnostic role of 18F-choline, 18F-fluciclovine and 18F-PSMA PET\/CT in the detection of prostate cancer with biochemical recurrence: a meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155685982500001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155685982500001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:30:19Z","timestamp":1762551019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155685982500001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S155685982500001X"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2025.01.001","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating Prostate Specific Membrane Antigen-PET into Clinical Practice for Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2025.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}